Smartphone Behavior and Epilepsy Management

Sponsor
Stichting Epilepsie Instellingen Nederland (Other)
Overall Status
Recruiting
CT.gov ID
NCT04617418
Collaborator
Leiden University (Other)
100
3
28.8
33.3
1.2

Study Details

Study Description

Brief Summary

In this prospective cohort study smartphone behavior surrounding epileptic seizures will be quantified, using a smartphone app, in order to optimize epilepsy evaluation and treatment

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Change in touchscreen interactions

Detailed Description

Rationale:

The unpredictability of seizures and the unclear behavioral outcomes are major concerns for people with epilepsy and may surface as increased anxiety about independence. This unpredictability is also a true obstacle in capturing and studying seizure-related neurobehavioral alterations themselves. Also, seizures often impact consciousness and thus may go unnoticed. As a result, subjective seizure diaries are unreliable. Continuous smartphone-based monitoring of behavioral output is a fast-emerging topic and proven fruitful in monitoring other neurological disease states. In the field of epilepsy, these tools are yet to be introduced.

Objective:

The investigators hypothesize that quantifying smartphone behavior will help obtain a detailed and objective behavioral map of seizures that can complement existing subjective seizure diaries and thereby improve the way epilepsy treatments are evaluated in daily practice.

Study design:

A multicentre observational prospective cohort study with at least 3 months follow-up.

Study population:

100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month.

Main study parameters/endpoints:

Change in touchscreen interactions (tapping speed, texting speed, apps used, location, sleep-wake cycles) surrounding reported epileptic seizures.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Using Day-to-day Behavior on Smartphones to Improve Epilepsy Management
Actual Study Start Date :
Nov 3, 2020
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
subjects with refractory focal epilepsy with a seizure frequency

The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.

Behavioral: Change in touchscreen interactions
The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions

Outcome Measures

Primary Outcome Measures

  1. Changes in tapping speed surrounding reported epileptic seizures [3 months]

    The tapping speed will be measured using the TapCounter app by QuantActions

  2. Changes in number of apps used surrounding reported epileptic seizures [3 months]

    The number of apps used will be measured using the TapCounter app by QuantActions

  3. Changes in time spent using the smartphone surrounding reported epileptic seizures [3 months]

    The phone usage in hours will be measured using the TapCounter app by QuantActions

  4. Changes in speed of unlocking the smartphone surrounding reported epileptic seizures [3 months]

    The unlocking speed will be measured using the TapCounter app by QuantActions

Secondary Outcome Measures

  1. Recovery after seizure [3 months]

    See how long does it take to behaviorally recover after a seizure, this will be assessed using the TapCounter app and seeing when phone usage before and after the reported seizure are similar again

  2. Comparison of seizures in diaries and seizures in app use [3 months]

    See if reported seizure incidence matches with seizure incidence deducted from smartphone measurements

  3. Subgroup analysis [3 months]

    Analyze differences in behavioural patterns between individuals with different types of epilepsy (e.g. different seizure types or onset zones)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥ 18 years of age

  • clinical diagnosis of refractory focal epilepsy meeting ILAE criteria16, 17

  • supported by at least one of the following; (1) interictal EEG with epileptiform discharges, (2) epileptogenic lesion on MRI corresponding to the presumed seizure onset zone, or (3) seizure recorded during a video-EEG

  • have a seizure frequency of ≥ 1 per month

  • only one seizure type, or in case of multiple seizure types only seizures that correspond to one probable onset zone (e.g. focal and focal to bilateral tonic-clonic seizures)

  • have daytime seizures (exclusively or both daytime and night-time seizures)

  • mentally competent and with no learning disabilities

  • able to keep a seizure diary including time and date (as judged by the treating physician)

  • have an Android-operating smartphone

  • use their phone with at least 5 distinct smartphone apps at a minimum of 5 days a week

Exclusion Criteria:
  • not fulfilling the above mentioned inclusion criteria

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kempenhaeghe Heeze Noord-Brabant Netherlands 5591 VE
2 Stichting Epilepsie Instellingen Nederland Heemstede Noord-Holland Netherlands 2103 SW
3 Maasstad ziekenhuis Rotterdam South Holland Netherlands 3079 DZ

Sponsors and Collaborators

  • Stichting Epilepsie Instellingen Nederland
  • Leiden University

Investigators

  • Principal Investigator: Roland D Thijs, MD PhD, Stichting Epilepsie Instellingen Nederland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stichting Epilepsie Instellingen Nederland
ClinicalTrials.gov Identifier:
NCT04617418
Other Study ID Numbers:
  • SB&EM
First Posted:
Nov 5, 2020
Last Update Posted:
Jun 28, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2022